The North America Sickle Cell Disease Treatment Market would witness market growth of 27.0% CAGR during the forecast period (2023-2030).
Sickle cell disease (SCD) is a group of inherited red blood cell disorders caused by a genetic mutation affecting hemoglobin, which transports oxygen and is found in red blood cells. The disease impacts red blood cells with sickle shapes, resulting in defective hemoglobin and improper blood flow. The most prevalent symptoms of sickle cell disease are shortness of breath and fatigue.
According to the Centres for Disease Control and Prevention (CDC), the estimated number of SCD sufferers in the United States is 100,000. The industry is anticipated to be driven by rising immigration, improved healthcare services, and a sizable population of African heritage.
The main medications authorized for treating SCD by the US FDA are hydroxyurea and Endari as of 2018. Additionally, the forthcoming commercialization of medications, including voxelotor, CTX001, and Mitapivat, is anticipated to fuel market expansion. Blood transfusions, antibiotics to cure infections, and drugs to ease symptoms brought on by complications of sickle cell anemia are the usual treatments healthcare providers use to treat sickle cell anemia.
In North America, homozygous HbS disease, an autosomal recessive illness, is the most prevalent kind of SCD. Vaso-occlusive crises happen in about half of people with homozygous HbS illness. The occurrence of crises can occur at any time. Some people experience up to six episodes a year, but others may only experience them rarely or never. The frequency of crises normally follows a predictable pattern for each person. Both the United States and Canada have diverse populations, and SCD disproportionately affects certain ethnic groups, such as those of African, Mediterranean, Middle Eastern, and South Asian descent. As these populations continue to grow, the demand for tailored treatments and specialized healthcare services for SCD will also increase.
The US market dominated the North America Sickle Cell Disease Treatment Market by Country in 2022 and would continue to be a dominant market till 2030; thereby, achieving a market value of $1,908.1 Million by 2030. The Canada market is experiencing a CAGR of 29.9% during (2023 - 2030). Additionally, The Mexico market would exhibit a CAGR of 28.8% during (2023 - 2030).
Based on Treatment, the market is segmented into Blood Transfusion, Pharmacotherapy, and Bone Marrow Transplant. Based on End-Use, the market is segmented into Hospitals, Specialty Clinics and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
Free Valuable Insights: The Worldwide Sickle Cell Disease Treatment Market is Projected to reach USD 7.3 Billion by 2030, at a CAGR of 27.9%
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Novartis AG, Pfizer Inc., bluebird bio, Inc., CSL Limited, Emmaus Life Sciences, Inc., Bristol Myers Squibb Company, CRISPR Therapeutics AG, Agios Pharmaceuticals, Inc. (LES LABORATOIRES SERVIER SAS), Novo Nordisk A/S and Medunik USA (Duchesnay Inc.).
By Treatment
By End-Use
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
